GCG and Alzheimer disease: After completing a phase 2b/3 study of the c-kit inhibitor masitinib in mild and moderate AD, AB Science released positive but limited data in December, and another anti-inflammatory therapy, Novo Nordisk’s glucagon-like peptide-1 (GLP1) analog semaglutide, is entering a phase 3 trial early this year.